## STZ: Constellation Brands, Inc. - XLP: Consumer Defensive

### Executive Summary

No thesis match: MRS_10 0.8% below STRENGTH zone (3.0-6.0%); PEG 1.58 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($131.86)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 4
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Franklin Resources Inc. Cuts Position in Donaldson Company, Inc. $DCI**
- Source: MarketBeat | 20251201T090848 | Somewhat-Bullish | Relevance: 65%
- Franklin Resources Inc. significantly reduced its stake in Donaldson Company, Inc. by 20.1% in Q2, selling 37,948 shares and ending with 150,691 shares valued at $10.45 million. Despite this, Donaldson maintains a "Moderate Buy" analyst rating and recently announced a quarterly dividend of $0.30 per share. Other institutional investors showed varied activity, with some increasing and others acquiring new stakes in the company.

**2. JPMorgan Chase & Co. Buys 175,587 Shares of Molson Coors Beverage Company $TAP**
- Source: MarketBeat | 20251202T103259 | Neutral | Relevance: 63%
- JPMorgan Chase & Co. increased its stake in Molson Coors Beverage Company ($TAP) by 20.4%, acquiring an additional 175,587 shares, bringing their total ownership to 1,036,110 shares valued at approximately $49.83 million. This increase in institutional investment comes as Molson Coors reported an earnings miss for the quarter and set its FY2025 guidance, maintaining an average "Hold" rating from analysts with a target price of $53.59. The company also declared a quarterly dividend of $0.47, reflecting a 4.0% yield.

**3. JPMorgan Chase & Co. Grows Position in Disc Medicine, Inc. $IRON**
- Source: MarketBeat | 20251202T103259 | Neutral | Relevance: 58%
- JPMorgan Chase & Co. increased its stake in Disc Medicine, Inc. (NASDAQ:IRON) by 11.1% in Q2 2025, now owning 843,616 shares valued at approximately $44.68 million. Institutional investors collectively own 83.70% of the company, while insiders sold shares worth about $16.9 million in the last quarter, reducing their ownership to 3.64%. Analysts have a "Moderate Buy" consensus rating with an average price target of $119.10 for Disc Medicine, which is currently trading around $91.85.

**4. Federal Realty Investment Trust stock price target raised to $109 by Truist By Investing.com**
- Source: Investing.com South Africa | 20251201T195400 | Neutral | Relevance: 57%
- Truist Securities increased its price target for Federal Realty Investment Trust (FRT) to $109 from $105, while maintaining a Hold rating. The adjustment reflects FRT's recent "relatively strong 3Q25 results" and strategic acquisitions, despite the stock underperforming the broader REIT market year-to-date. InvestingPro data highlights FRT's low price volatility, consistent dividend payments for 53 years, and expected profitability, even as it manages short-term obligations and aggressive acquisition strategies.

### Analyst Activity

**Target Signal:** BEARISH (Raises: 0, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-21 | Piper Sandler | $135 | $155 | -13% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-21 | Piper Sandler | main | Neutral |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 44.0% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 3 / 6 |

**Top Holders:**
- Vanguard Group Inc: 10.5% (+3.2%)
- Berkshire Hathaway, : 7.7% (0.0%)
- Blackrock Inc.: 6.1% (-2.0%)
- Capital World Invest: 3.8% (-43.3%)
- State Street Corpora: 3.8% (-4.2%)

### Key Risks

1. Long-term trend broken: trading 15.5% below SMA200.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_10 improving +1.1% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 1.58 elevated, pricing in significant growth expectations. Analyst sentiment negative (1 target cuts vs 0 raises). Institutional flow bearish (6 selling vs 3 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $25.9B |
| Beta | 0.46 |
| 52W Range | $126.45 - $244.69 |
| Short Interest | 6.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.58 |
| Forward P/E | 11.1 |
| Current P/E | 12.0 |
| YoY Growth | 8.0% |
| EPS Direction | FALLING |

### Technicals

MRS_10 strengthening from -0.4% to 0.8% (+1.1% in 5 days), confirming momentum buildup. Below STRENGTH zone by 2.2pp (needs >3.0% for momentum thesis). MRS_5 at 0.8% confirms short-term momentum alignment. Below SMA200 (0.84x), long-term trend not supportive. MACD histogram positive (1.27), confirming momentum.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 0.77% (CS: 75) | Neutral |
| RSI_14 | 60.8 | Neutral |
| MACD Histogram | 1.27 | Bullish |
| vs SMA20 | 1.048x | Above |
| vs SMA50 | 1.020x | Above |
| vs SMA200 | 0.845x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $137.86
- **Stop Loss:** $131.86 (4.4% risk)
- **Target:** $143.86 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 166
- **Position Value:** $22,884.76
- **Portfolio %:** 22.88%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate improvement trajectory. VIX compression from 20.5 to 16.6 over 5 days signals declining fear, while 47% breadth shows narrow but recovering participation. Fed meeting in 6 days creates near-term uncertainty, but AI sector momentum and improving technical setups support selective positioning.*

### Earnings

**Next:** 2026-01-07 (Est: $2.65)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.41 | $3.63 | +6.5% |
| 2025Q2 | $3.29 | $3.22 | -2.3% |
| 2025Q1 | $2.27 | $2.63 | +15.9% |
| 2024Q4 | $3.31 | $3.25 | -1.9% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*